Contact Us Today|info@empharmd.com

What I Bring When Attending A Code

Pharmacists have been shown to improve adherence to advanced cardiovascular life support (ACLS) guidelines (1,2), and pharmacist involvement adds instant drug expertise during intense situations. Not to mention, the multidisciplinary team wants us there at the bedside. Nurses and providers surveyed have overwhelmingly (97%) believed that having a pharmacist present during a medical resuscitation enhances their ability to deliver safe, quality care to patients.(3) The large amount of code cart drugs suffering from national shortages [...]

By |2017-08-30T10:00:00-05:00August 30th, 2017|EM PharmD Blog|0 Comments

TXA Isn’t For Everyone: Fibrinolysis Shutdown in Traumatically Injured Patients

Tranexamic acid (TXA), an antifibrinolytic agent used to prevent clot breakdown in hemorrhaging trauma patients, has been shown in the CRASH-2, MATTERS, and PED-TRAX trials to reduce overall mortality in adult and pediatric patients.1-3 Additional mortality benefits were seen in the MATTERS trial among patients who received a massive transfusion protocol (MTP) with a number needed to treat (NNT) of 15 in the overall cohort compared to a NNT of 7 in MTP cohort.2 Although [...]

By |2017-08-18T12:45:00-05:00August 18th, 2017|EM PharmD Blog|0 Comments

SCCM VCCR Podcast: Acetaminophen Toxicity and the Rumack-Matthew Nomogram

I recently had the opportunity of recording a podcast episode for the Virtual Critical Care Rounds (VCCR) of the Society of Critical Care Medicine (SCCM) with Sean Kane, PharmD, BCPS (@ClinCalc). We discussed the nuances of acetaminophen toxicity and practical application of the Rumack-Matthew nomogram in the clinical setting. You can find the link to the podcast episode here (as well as other episodes of the SCCM VCCR). Some suggested references for the episode are [...]

By |2017-05-25T13:10:00-05:00May 25th, 2017|EM PharmD Blog|0 Comments

Safety of Ondansetron in Pregnancy

IntroductionNausea and vomiting is a common ailment in pregnancy affecting approximately 70 to 80% of all pregnant women. (1) Ondansetron, a 5-HT3 receptor antagonist, is commonly used to treat nausea and vomiting of varying etiologies including hyperemesis gravidarum. (2) Recently the safety of ondansetron in pregnancy has been called into question. Concern for fetal abnormalities, including cardiac malformations and cleft palates caused by ondansetron have been raised, leading to a petition to the Food and [...]

By |2017-05-11T13:26:00-05:00May 11th, 2017|EM PharmD Blog|0 Comments

SCCM VCCR Podcast – ACEi Angioedema Plus Sacubitril and DPP-IV inhibitors

I had the chance to talk with Sean P. Kane, PharmD, BCPS about angiotensin-converting enzyme (ACE) inhibitor-induced angioedema. And it was recorded!As part of the SCCM VCCR podcast, this episode we spoke about a variety of treatment approaches for ACE inhibitor-induced angioedema are discussed, including fresh frozen plasma, ecallantide, icatibant, and conventional therapies for undifferentiated angioedema. Here is the link, and some show notes to go along with it.Compared to a type 1 IGE mediated [...]

By |2017-05-03T12:50:00-05:00May 3rd, 2017|EM PharmD Blog|0 Comments

Methotrexate, Obesity, and Ectopic Pregnancy

Obstetric emergencies can be challenging to many pharmacists given the critical nature of these diseases and the need for immediate recall of medication information ranging from teratogenicity to second/third line agents in light of drug shortages.(1-4) Ectopic pregnancy is one of those scenarios where advanced knowledge and comprehension of the medical management is essential for pharmacists working in emergency departments. This, in large part, is as a result of the frequent use of methotrexate for [...]

By |2017-04-16T15:30:00-05:00April 16th, 2017|EM PharmD Blog|0 Comments

I’ve Felt the Burn, and Live to Tell About It

After 6 years of experience since completion of my residency training, I have felt a tremendous amount of growth. As I have said earlier, the more experience I gain, the more I respect those who have it, and realize how little I truly have. There is no hidden meaning or cryptic message. Rather than resisting advice or guidance, I now listen to someone who's been through it all and come out wiser. It's such an [...]

By |2017-03-17T12:54:00-05:00March 17th, 2017|EM PharmD Blog|0 Comments

I've Felt the Burn, and Live to Tell About It

After 6 years of experience since completion of my residency training, I have felt a tremendous amount of growth. As I have said earlier, the more experience I gain, the more I respect those who have it, and realize how little I truly have. There is no hidden meaning or cryptic message. Rather than resisting advice or guidance, I now listen to someone who's been through it all and come out wiser. It's such an [...]

By |2017-03-17T12:54:00-05:00March 17th, 2017|EM PharmD Blog|0 Comments

Revisiting Esmolol for Refractory Ventricular Fibrillation in Cardiac Arrest

A 63-year-old male arrives to the resuscitation bay in cardiac arrest with ongoing cardiopulmonary resuscitation (CPR). Per EMS, the patient was found in ventricular fibrillation (Vfib) and has received defibrillation 6 times with four rounds of epinephrine and 2 doses of amiodarone (300 mg, 150 mg) prior to arrival. In the emergency department (ED), the patient is noted to still be in Vfib and a dose of 1 mg/kg of lidocaine is administered without termination [...]

By |2017-03-13T10:00:00-05:00March 13th, 2017|EM PharmD Blog|0 Comments

Antihistamines for Analgesia: Down to the Bone (Pain)

Clinicians in emergency departments across the country have increasingly become more savvy in their approach to the management of common pain conditions that patients may present with in this setting. In the effort to overcome the effects and consequences of the opioid abuse epidemic, great emphasis is now being placed in leveraging opioid-free alternatives in new ways for the management of these frequently encountered common pain conditions. This may involve utilizing target-specific agents in the [...]

By |2017-03-02T11:00:00-05:00March 2nd, 2017|EM PharmD Blog|0 Comments